Peter J Houghton
Overview
Explore the profile of Peter J Houghton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
317
Citations
9677
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li F, Bondra K, Wang H, Kurmashev D, Mukherjee B, Kanji S, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40083135
Background: MAPK pathway inhibitors (MAPKi) have shown significant efficacy in treating childhood BRAF-activated brain tumors. For tumors harboring BRAFV600E mutations, the drugs are rarely curative, and patients can become refractory...
2.
Smith M, Houghton P, Lock R, Maris J, Gorlick R, Kurmasheva R, et al.
Pharmacol Ther
. 2024 Nov;
264:108742.
PMID: 39510293
Programs for preclinical testing of targeted cancer agents in murine models of childhood cancers have been supported by the National Cancer Institute (NCI) since 2004. These programs were established to...
3.
Suvarna K, Jayabal P, Ma X, Wang H, Chen Y, Weintraub S, et al.
Cell Rep
. 2024 Jul;
43(8):114497.
PMID: 39024100
Ewing sarcoma is a cancer of bone and soft tissue in children and young adults primarily driven by the EWS-FLI1 fusion oncoprotein, which has been undruggable. Here, we report that...
4.
5.
Pomella S, Cassandri M, DArchivio L, Porrazzo A, Cossetti C, Phelps D, et al.
Nat Commun
. 2023 Dec;
14(1):8373.
PMID: 38102140
Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic transcription factor MYOD that, whilst...
6.
He F, Bandyopadhyay A, Klesse L, Rogojina A, Chun S, Butler E, et al.
Nat Commun
. 2023 Nov;
14(1):7600.
PMID: 37990009
Subcutaneous patient-derived xenografts (PDXs) are an important tool for childhood cancer research. Here, we describe a resource of 68 early passage PDXs established from 65 pediatric solid tumor patients. Through...
7.
Rogojina A, Klesse L, Butler E, Kim J, Zhang H, Xiao X, et al.
iScience
. 2023 Nov;
26(11):108171.
PMID: 37915590
Patient-derived xenografts (PDX) remain valuable models for understanding the biology and for developing novel therapeutics. To expand current PDX models of childhood leukemia, we have developed new PDX models from...
8.
Mooney B, Negri G, Shyp T, Delaidelli A, Zhang H, Spencer Miko S, et al.
Clin Cancer Res
. 2023 Oct;
30(5):1022-1037.
PMID: 37812652
Purpose: Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with...
9.
Nayak T, Wang L, Ning M, Rubannelsonkumar G, Jin E, Zheng S, et al.
Bioinform Adv
. 2023 Jun;
3(1):vbad076.
PMID: 37359725
Motivation: Large-scale genetic and pharmacologic dependency maps are generated to reveal genetic vulnerabilities and drug sensitivities of cancer. However, user-friendly software is needed to systematically link such maps. Results: Here,...
10.
Kitagawa R, Niikura Y, Becker A, Houghton P, Kitagawa K
Cell Rep
. 2023 May;
42(6):112568.
PMID: 37243594
The centromere is essential for ensuring high-fidelity transmission of chromosomes. CENP-A, the centromeric histone H3 variant, is thought to be the epigenetic mark of centromere identity. CENP-A deposition at the...